GlassScriptPhysician profile
Sherry Spacek-Llanas
NPI 1568801629
$10,318.90
in general payments reported to CMS, 2019-2025
53 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,183 · 2020: $1,254 · 2021: $1,766 · 2022: $1,356 · 2023: $1,508 · 2024: $1,820 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,759.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,142.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,098.79 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $704.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $690.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $562.30 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $503.14 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.10 | 2019-2025 | Jardiance, Spiriva Respimat |
| Lilly USA, LLC | $447.31 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $414.87 | 2019-2025 | Veozah, Myrbetriq |
| Amgen INC. | $381.38 | 2019-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $376.31 | 2019-2024 | Steglatro, Belsomra, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $341.04 | 2019-2023 | |
| Amarin Pharma, INC. | $289.33 | 2019-2022 | |
| Exact Sciences Corporation | $270.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $254.83 | 2019-2020 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Spacek-Llanas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.